Ep. 342 - 2026 Biotech Kickoff скачать в хорошем качестве

Ep. 342 - 2026 Biotech Kickoff

The New Year begins with biotech running along parallel storylines. There’s cause for optimism as the industry’s financing gears have begun to churn again and innovation remains as strong as it has ever been, while there's cause for concern as the world’s most stable, progressive, science-based regulatory system has become unpredictable amid new leadership at HHS, FDA, and NIH. On the first episode of the BioCentury This Week podcast’s seventh year, BioCentury’s analysts assess the state of play for biotech in the U.S., Europe, and Asia. The discussion ranges from recent changes at NIH to what’s next for rare pediatric disease priority review vouchers (https://www.biocentury.com/article/65...) , and from Europe’s opportunity as FDA enters uncertain terrain to Japan’s evolving biotech landscape (https://www.biocentury.com/article/65...) . Early bird rates for BioCentury and BayHelix’s fifth East-West Biopharma Summit end Friday. Act now (https://on.lenos.com/biocentury/EastW...) to join investors, dealmakers and innovators in Seoul this March to source innovation from Asia, or accelerate your own pipeline by finding the right Asia partner. View full story: https://www.biocentury.com/article/65... #BiotechOutlook #FDAUncertainty #GlobalBiotech #RarePediatricDiseasePRV #NIHLeadership 00:00 - Introduction 01:46 - 2026 Outlook 03:56 - Policy Landscape 11:48 - Priority Review Vouchers 15:03 - Global Perspectives 16:57 - Spotlight on Japan 21:55 - European Biotech Opportunities To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text (https://www.buzzsprout.com/twilio/tex...)